2-溴-1-(4-甲氧基苯基)己烷-1-酮 | 33809-55-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-溴-1-(4-甲氧基苯基)己烷-1-酮
• 英文名称: 2-bromo-1-(4'-methoxyphenyl)-hexan-1-one
• 英文别名: 1-Hexanone, 2-bromo-1-(4-methoxyphenyl)-；2-bromo-1-(4-methoxyphenyl)hexan-1-one
• CAS: 33809-55-1
• 化学式: C₁₃H₁₇BrO₂
• 分子量: 285.181
• InChiKey: GAQLVKVMOILKSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-溴-1-(4-甲氧基苯基)己烷-1-酮 在 sodium azide 、 三氟二甲基硫醚络合物 、 水 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 C₂₄H₂₈N₂O₂
  参考文献：
  名称：

  Estrogenic diazenes: heterocyclic non-steroidal estrogens of unusual structure with selectivity for estrogen receptor subtypes

  摘要：

  Estrogens regulate many biological functions, often acting in a tissue-selective manner. Their tissue-selective action is believed to involve differential estrogen action through the two estrogen receptor (ER) subtypes, ERalpha and ERbeta, as well as differential interaction of the ligand-receptor complexes with promoters and coregulator proteins. In the latter case, selectivity is based on the induction of specific conformations of the ligand-ER complex, conformations that are influenced by the structure of the ligand. Estrogen pharmaceuticals having an ideal balance of tissue-selective activity are being sought for menopausal hormone replacement, breast cancer prevention and therapy, and other actions. To expand on the structural diversity of ER ligands that might show such tissue selectivity, we have prepared a series of diazenes (pyrazines, pyrimidines, and pyridazines) substituted with two to four aryl groups and various short-chain aliphatic substituents. All of the pyrazine and pyrimidines bind to ER, some with high affinity and with a considerable degree of preferential binding to either ERalpha or ERbeta. One pyrimidine and one pyrazine have ERalpha affinity preferences as high as 23 and 9, respectively, and one pyrimidine has an ERP affinity preference of 8. The pyridazines, by contrast, are quite polar and have only very low binding affinity for the ER. In cell-based transcription assays, several of the pyrimidines and a pyrazine were found to be considerably more agonistic on ERalpha than on ERbeta. Because these triaryl diazenes have the largest volumes among the ER ligands so far investigated, their high affinity demonstrates the flexibility of the ligand binding pocket of the ERs and its tolerance for large substituents. Thus, these novel heterocyclic ligands expand the repertoire of chemical structures that bind to the estrogen receptor, and they could prove to be useful in elucidating the biological behavior of the two ER subtypes and in forming the basis for new estrogen pharmaceuticals having desirable tissue selectivity. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00309-7
• 作为产物：
  描述：

  4'-甲氧基苯己酮 在 三氯化铝 溴 作用下， 以 乙醚 为溶剂， 以90%的产率得到2-溴-1-(4-甲氧基苯基)己烷-1-酮
  参考文献：
  名称：

  一系列新型呋喃的合成和生物学评估：对雌激素受体α选择性的配体。

  摘要：

  多种非甾体系统可以充当雌激素受体（ER）的配体，在某些情况下，它们对两种ER亚型之一ERα或ERβ表现出选择性。我们为雌激素受体准备了一系列基于杂环的（呋喃，噻吩和吡咯）配体，并评估了它们作为ER配体的行为。开发了醛烯酮共轭加成方法和烯醇烷基化方法以制备分别为三取代和四取代系统的前体的1，4-二酮系统。所有的二酮都容易转化为相应的呋喃，但是由取代程度更高的1,4-二酮形成噻吩和吡咯是有问题的。在研究的系统中，四取代的呋喃被证明是最有趣的。它们是ERα结合和效能选择剂，三酚3-烷基-2,4,5-三（4-羟苯基）呋喃（15a-d）通常显示出比双酚类似物（15f-一世）。ERα的结合选择性高达50-70倍，转录激活研究表明，该系列的几个成员是ERα选择性激动剂，具有最佳化合物[3-ethyl-2,4,5-tris（4 -羟基苯基）呋喃，15b]对ER alpha具有完全的转录活性，而对ER be

  DOI：

  10.1021/jm010211u

文献信息

• Synthesis and Biological Evaluation of a Novel Series of Furans:  Ligands Selective for Estrogen Receptor α
  作者：Deborah S. Mortensen、Alice L. Rodriguez、Kathryn E. Carlson、Jun Sun、Benita S. Katzenellenbogen、John A. Katzenellenbogen

  DOI：10.1021/jm010211u

  日期：2001.11.1

  converted into the corresponding furans, but formation of the thiophenes and pyrroles from the more highly substituted 1,4-diones was problematical. Of the systems investigated, the tetrasubstituted furans proved to be most interesting. They were ER alpha binding- and potency-selective agents, with the triphenolic 3-alkyl-2,4,5-tris(4-hydroxyphenyl)furans (15a-d) displaying generally higher subtype binding

  多种非甾体系统可以充当雌激素受体（ER）的配体，在某些情况下，它们对两种ER亚型之一ERα或ERβ表现出选择性。我们为雌激素受体准备了一系列基于杂环的（呋喃，噻吩和吡咯）配体，并评估了它们作为ER配体的行为。开发了醛烯酮共轭加成方法和烯醇烷基化方法以制备分别为三取代和四取代系统的前体的1，4-二酮系统。所有的二酮都容易转化为相应的呋喃，但是由取代程度更高的1,4-二酮形成噻吩和吡咯是有问题的。在研究的系统中，四取代的呋喃被证明是最有趣的。它们是ERα结合和效能选择剂，三酚3-烷基-2,4,5-三（4-羟苯基）呋喃（15a-d）通常显示出比双酚类似物（15f-一世）。ERα的结合选择性高达50-70倍，转录激活研究表明，该系列的几个成员是ERα选择性激动剂，具有最佳化合物[3-ethyl-2,4,5-tris（4 -羟基苯基）呋喃，15b]对ER alpha具有完全的转录活性，而对ER be
• TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF
  申请人：Li Song

  公开号：US20090298832A1

  公开（公告）日：2009-12-03

  The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.

  本发明涉及公式（I）的2,4,5-三取代噻唑化合物或所有可能的异构体、前药、药用盐、溶剂合物或水合物，用于抑制血浆PLTP活性和/或血浆CETP活性，其中取代基如规范中定义；一种用于制备公式（I）化合物的方法；包括公式（I）化合物的药物组合物以及其用于制备治疗和/或预防与哺乳动物体内增加的血浆PLTP活性和/或增加的血浆CETP活性相关的疾病的药物的用途，如动脉粥样硬化、心血管疾病和周围血管疾病等。
• Trisubstituted thiazole compounds, preparations methods, pharmaceutical compositions and medicals uses thereof
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.C. China

  公开号：US08053581B2

  公开（公告）日：2011-11-08

  The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.

  本发明涉及公式(I)的2,4,5-三取代噻唑化合物或其所有可能的异构体、前药、药学上可接受的盐、溶剂化合物或水合物，用于抑制血浆PLTP活性和/或血浆CETP活性，其中取代基如规范中所定义；一种制备公式(I)化合物的方法；包括公式(I)化合物的制药组合物以及其用于制备哺乳动物（如动脉粥样硬化、心血管疾病和周围血管疾病等）的治疗和/或预防与增加的血浆PLTP活性和/或增加的血浆CETP活性相关的疾病的药物的用途。
• 2,4,5-TRISUBSTITUTED THIAZOLE COMPOUNDS,PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A.

  公开号：EP2042494A1

  公开（公告）日：2009-04-01

  The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.

  本发明涉及用于抑制血浆PLTP活性和/或血浆CETP活性的式(I)的2,4,5-三取代噻唑化合物或其所有可能的异构体、原药、药学上可接受的盐、溶液或水合物，其中取代基如说明书中所定义；制备式(I)化合物的工艺；一种包含式（I）化合物的药物组合物及其用于制备治疗和/或预防与哺乳动物血浆 PLTP 活性升高和/或血浆 CETP 活性升高有关的疾病（如动脉粥样硬化、心血管疾病和外周血管疾病等）的药物。
• 2,4,5-trisubstituted thiazole compounds,preparation methods,pharmaceutical compositions and medical uses thereof
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L. A. China

  公开号：EP2772488A1

  公开（公告）日：2014-09-03

  The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.

  本发明涉及用于抑制血浆PLTP活性和/或血浆CETP活性的式(I)的2,4,5-三取代噻唑化合物或其所有可能的异构体、原药、药学上可接受的盐、溶液或水合物，其中取代基如说明书中所定义；制备式(I)化合物的工艺；一种包含式（I）化合物的药物组合物及其用于制备治疗和/或预防与哺乳动物血浆 PLTP 活性升高和/或血浆 CETP 活性升高有关的疾病（如动脉粥样硬化、心血管疾病和外周血管疾病等）的药物。